• Le lot 1, « scenarii médicaux », dont RBC est responsable a pour but de définir les pathologies, les services, les technologies et les usages en collaboration avec les professionnels de santé et futurs utilisateurs du système.
• Le lot 2, « volet technologique », vise à concevoir la plateforme de Domomédecine en développant et mettant en œuvre une architecture urbanisée permettant l’interconnexion de toutes les composantes de la chaîne de manière ouverte, sécurisée, performante.
• Le lot 3, « volet expérimentation et évaluation (démonstrateur) »,  sous la responsabilité de RBC, prévoit la réalisation d’une toute première expérimentation de Domomédecine. Cette démonstration permettra d’élaborer un premier modèle économique d’un nouveau système de santé impliquant conjointement des organismes de soin, des professionnels de santé, des institutions académiques et des partenaires industriels.

L'objectif de CANCERSENSOR est de développer et valider un outil de diagnostic quantitatif et non-invasif permettant d'évaluer l'éfficacité des chimiothérapies chez le patient atteint de cancer colorectal et de suivre ces mêmes patients après la resection chirurgicale de la maladie.

Description du projet en anglais:

Colorectal cancer is the second cause of cancer-related deaths. Once colon cancer spreads beyond the colon, into the lymph nodes or into other areas of the body, it is then harder to treat. It is thus very important to can detect as earlier as possible a cancer, to treat it fast, to check for the efficacy of treatments and for any recurrence. The therapeutic drug monitoring of antineoplastic agents is at this time restricted by several factors, such as the lack of established therapeutic concentration ranges, a considerable inter- or intra-individual pharmacokinetic variability, a relationship linking toxicity to systemic exposure, and complicate pharmacodynamics of drug toxicity. To circumvent those limitations and evaluate the success of chemotherapy is to correlate a cancer treatment with the amount of tumour markers, a substance that can be found in the body when cancer is present. It has been reported that cancer patients excrete in their urine an abnormal increased amounts of modified nucleosides, which are formed at the post-transcriptional stage by chemical modification of normal nucleosides within the RNA. These modified nucleosides cannot be reutilized or further degraded, but they are excreted in the urine as intact molecules. The elevated levels of modified nucleosides in the urine samples have served as potential cancer biomarkers in many studies. Although different analytical techniques have been reported for determination of nucleosides levels, they are practically difficult to use as a routine tool for therapy control of colorectal cancer.

Goals of this proposal are to develop and validate a quantitative, non-invasive diagnostic tools to follow-up the chemotherapy of colorectal cancer and monitor the disease response to chemotherapeutics. A methodology will be developed making use of a combination of the probably most exciting recent advances in the field of acoustic-biosensor based on molecularly imprinted polymers (MIP). It includes advances which will take the sensitivity down to a low-concentration single-molecule level. Apart from detecting and identifying tumour markers in the urine samples, the effect of circadian chemotherapy on the amount of cancer markers, using the developed tools will be explored. This is to date an almost unexploited dimension of diagnostic information. By combining and supporting these novel optical methods with state-of-the-art affinity molecule MIP technology, tumour biomarkers, acoustic biosensor, will be exploited to extract a maximum amount of information out of very small amounts of sample material. Given the high incidence of colorectal cancer, this project has a very high relevance. Those tools will be used, within the frame of this project, to analyze more than 3000 urinary samples from patients under chemotherapy for colorectal cancer and to correlate the chemotherapy treatment with the circadian time of infusion and the circadian variations of clearance.

The need for development of rapid, sensible, easy-to-use and cost effective sensors for surveillance of pre- and post-operative CRC is evident and of huge interest. This approach could deeply modify the manner of checking near each person the effectiveness of the chemotherapy treatment of colorectal cancer. At the end of this project, we will offers diagnostic products for colorectal cancer follow-up in the European market. It will have the ability to detect and recognize the expression of tumour-associated biomarkers in patients with metastatic cancer.